Recently, Wuhan Amison Life Technology Co., Ltd. (hereinafter referred to as "Amison" or the "Company") completed more than 100 million yuan of C round financing, this round of financing led by CCB International, Wuhan Hi-Tech, Sanya Xuanpan and other well-known institutions to follow. The investment funds will be used for market expansion, new product research and development, clinical trials, registration declarations, etc. The past investors also include CCB Medical Growth Fund, Kingfun Capital, Kaipu Bio, Changjiang Securities, etc.
Amison is a high-tech enterprise focusing on the research and development, registration, production and sales of early non-invasive detection products for high-incidence malignant tumors around the world. Combining epigenetics, bioinformatics, material science and clinical big data, the company has created the world's leading early tumor screening and early diagnosis technology platform, adhering to the product concept of "early, accurate, convenient and inclusive", the company has launched early non-invasive detection products covering digestive system tumors, gynecological tumors, urinary system tumors and pan-cancers and other types of high-incidence tumors.
The company has applied for more than 60 patents, authorized 25 patents, a number of PCT patents, and published more than 10 cutting-edge research results. The company has won many honors such as "Hubei Province Specialized Special New Little Giant", "Wuhan Top Ten Scientific and Technological Innovation Leading Enterprises", "Wuhan Listed Silver Seed Enterprise", "Optics Valley Gazelle Enterprise", "High-tech Enterprise" and so on.
At present, the company's colorectal cancer detection product "Ai Changkang" has been registered and certified by NMPA, which is the first dual-target fecal DNA methylation detection of colorectal cancer products in China, and the product has obtained the registration certificate of scientific and technological achievements of the Ministry of Industry and Information Technology and has reached the international advanced level by many experts. In addition, the company's cervical cancer, endometrial cancer and other early detection products for cancer have passed CE certification.
Ai Changkang was approved for listing,
Help the popularization of early screening and early diagnosis of bowel cancer
A growing body of research suggests that left and right colon cancers have significant differences in epidemiology, pathology, cytogenetics, and molecular characteristics, and should be considered two different diseases to some extent. The level of gene methylation in different parts of the intestine is different, and it is of clinical significance to improve the detection performance of colorectal cancer by different complementary markers of the left and right colons.
SDC2 and TFPI2 gene methylation joint detection kit (fluorescence PCR method) - Ai Changkang
Professor Bai Yu of Changhai Hospital made an image of single-gene methylation detection, dual-gene methylation joint detection and multi-gene detection: "Single-gene methylation detection is like a wide fishing net, multi-gene detection is like a densely woven fishing net, wide and sparse fishing nets are easy to let big fish leak away, and densely woven fishing nets are all large and small fish, and both types of fishing nets are not suitable." Fishing nets woven by the combined detection of dual-gene methylation with just the right density can be accurately fished. ”
Therefore, if you can find a suitable combination of targets, achieve a balance between sensitivity and specificity, so as to avoid missing the lesions associated with colorectal cancer as much as possible, and do not catch small lesions unrelated to colorectal cancer. This would be a better screening strategy.
Illustration of the left and right half colons
Aiming at the difference between the left and right colons, SDC2 methylation has a higher sensitivity to right half colon tumors, TFPI2 gene methylation has a higher sensitivity to left half colon tumors, and the combined detection of the two targets can comprehensively improve the detection sensitivity of left and right colon cancer. Ai Changkang's registered clinical research was carried out in Peking Union Medical College Hospital, the First Affiliated Hospital of Anhui Medical University, Central South Hospital of Wuhan University and other authoritative hospitals, and after prospective multi-center large sample case control studies, Ai Changkang had excellent detection ability for colorectal cancer and advanced adenoma, with a total sensitivity of 95.3% for CRC in each stage and 63.4% sensitivity for advanced adenoma.
Ai Changkang has carried out technical optimization in a number of key steps and process automation such as sample pretreatment, nucleic acid extraction, nucleic acid conversion, PCR detection, etc., and can complete a single sample detection in 4.5 hours, and can process up to 96 samples at a time. Through patented trace signal enrichment technology (AS-CAP) and methylation PCR sensitization technology, Ai Changkang has lower requirements on laboratory equipment and is more suitable for rapid completion of high-throughput detection tasks in medical scenarios. SDC2 and TFPI2 gene methylation joint detection (Ai Changkang) registered clinical research has yielded fruitful results, 5 research-related articles published in FRONT MOL BIOSCI, J MOL DIAGN and other authoritative journals, product applications and approval of a total of 26 national patents, the registered clinical research officially obtained the registration certificate of three types of medical devices. With the successful approval of THE NMPA, Ai Changkang can effectively achieve early diagnosis and treatment of colorectal cancer, greatly reducing and avoiding the socio-economic burden and public health resource pressure caused by late tumor detection.